IRIS Accounts Production v25.1.0.734 05680172 director 1.3.24 28.2.25 28.2.25 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh056801722024-02-29056801722025-02-28056801722024-03-012025-02-28056801722023-02-28056801722023-03-012024-02-29056801722024-02-2905680172ns15:EnglandWales2024-03-012025-02-2805680172ns14:PoundSterling2024-03-012025-02-2805680172ns10:Director12024-03-012025-02-2805680172ns10:PrivateLimitedCompanyLtd2024-03-012025-02-2805680172ns10:SmallEntities2024-03-012025-02-2805680172ns10:AuditExempt-NoAccountantsReport2024-03-012025-02-2805680172ns10:SmallCompaniesRegimeForDirectorsReport2024-03-012025-02-2805680172ns10:SmallCompaniesRegimeForAccounts2024-03-012025-02-2805680172ns10:FullAccounts2024-03-012025-02-2805680172ns10:RegisteredOffice2024-03-012025-02-2805680172ns5:CurrentFinancialInstruments2025-02-2805680172ns5:CurrentFinancialInstruments2024-02-2905680172ns5:ShareCapital2025-02-2805680172ns5:ShareCapital2024-02-2905680172ns5:FurtherSpecificReserve3ComponentTotalEquity2025-02-2805680172ns5:FurtherSpecificReserve3ComponentTotalEquity2024-02-2905680172ns5:RetainedEarningsAccumulatedLosses2025-02-2805680172ns5:RetainedEarningsAccumulatedLosses2024-02-2905680172ns5:ComputerEquipment2024-03-012025-02-2805680172ns5:PlantMachinery2024-02-2905680172ns5:PlantMachinery2024-03-012025-02-2805680172ns5:PlantMachinery2025-02-2805680172ns5:PlantMachinery2024-02-2905680172ns5:CostValuation2024-02-2905680172ns5:AdditionsToInvestments2025-02-2805680172ns5:RevaluationsIncreaseDecreaseInInvestments2025-02-2805680172ns5:CostValuation2025-02-2805680172ns5:WithinOneYearns5:CurrentFinancialInstruments2025-02-2805680172ns5:WithinOneYearns5:CurrentFinancialInstruments2024-02-2905680172ns5:CurrentFinancialInstruments2024-03-012025-02-2805680172ns5:DeferredTaxation2024-02-2905680172ns5:DeferredTaxation2025-02-2805680172ns5:FurtherSpecificReserve3ComponentTotalEquity2024-02-29
REGISTERED NUMBER: 05680172 (England and Wales)











Unaudited Financial Statements

for the Year Ended 28 February 2025

for

Lifescience Consultants Limited

Lifescience Consultants Limited (Registered number: 05680172)






Contents of the Financial Statements
for the Year Ended 28 February 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Lifescience Consultants Limited

Company Information
for the Year Ended 28 February 2025







DIRECTOR: Mrs K L Chandler-Male





REGISTERED OFFICE: Eldo House
Kempson Way
Bury St Edmunds
Suffolk
IP32 7AR





REGISTERED NUMBER: 05680172 (England and Wales)





ACCOUNTANTS: Knights Lowe Chartered Accountants
Eldo House
Kempson Way
Suffolk Business Park
Bury St Edmunds
Suffolk
IP32 7AR

Lifescience Consultants Limited (Registered number: 05680172)

Balance Sheet
28 February 2025

2025 2024
Notes £    £    £   
FIXED ASSETS
Tangible assets 4 1,690 1,767
Investments 5 804,825 646,436
806,515 648,203

CURRENT ASSETS
Debtors 6 23,412 25,481
Cash at bank 229,828 310,526
253,240 336,007
CREDITORS
Amounts falling due within one year 7 32,208 83,950
NET CURRENT ASSETS 221,032 252,057
TOTAL ASSETS LESS CURRENT LIABILITIES 1,027,547 900,260

PROVISIONS FOR LIABILITIES 8 36,788 11,477
NET ASSETS 990,759 888,783

CAPITAL AND RESERVES
Called up share capital 100 100
Fair value reserve 9 68,460 35,401
Retained earnings 922,199 853,282
SHAREHOLDERS' FUNDS 990,759 888,783

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 28 February 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 28 February 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Lifescience Consultants Limited (Registered number: 05680172)

Balance Sheet - continued
28 February 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 30 April 2025 and were signed by:





Mrs K L Chandler-Male - Director


Lifescience Consultants Limited (Registered number: 05680172)

Notes to the Financial Statements
for the Year Ended 28 February 2025

1. STATUTORY INFORMATION

Lifescience Consultants Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Office equipment - 25% on reducing balance

Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities such as trade and other accounts receivable and payable, and loans from banks or other related parties.

Debt instruments, such as loans and other accounts receivable and payable, are initially measured at present value of the future payments and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade payables or receivables, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received. However if the arrangements of a short-term instrument constitute a financing transaction, such as the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate, or in case of an outright short-term loan not at market rate, the financial asset or liability is measured, initially and subsequently, at the present value of the future payment discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Comprehensive Income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate, which is an approximation of the amount that the company would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Lifescience Consultants Limited (Registered number: 05680172)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2025

2. ACCOUNTING POLICIES - continued

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Impairment
At each reporting date, goodwill and other fixed assets, including tangible fixed assets and investments but excluding investment properties, are assessed to determine whether there is an indication that the carrying amount of an asset may be more than its recoverable amount and that the asset should be impaired. If there is an indication of possible impairment, the recoverable amount of an asset, which is the higher of its value in use and its net realisable value, is estimated and compared with its carrying amount. If the recoverable amount is lower, the carrying amount of the asset is written down to its estimated recoverable amount and an impairment loss is recognised in profit and loss.

Fixed asset investments
Fixed asset investments have been measured at fair value through a revaluation. The revaluation of investments has been measured as the difference between the historical cost of the investments and the market value at the balance sheet date.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2024 - 1 ) .

Lifescience Consultants Limited (Registered number: 05680172)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2025

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 March 2024 5,758
Additions 666
Disposals (1,728 )
At 28 February 2025 4,696
DEPRECIATION
At 1 March 2024 3,991
Charge for year 434
Eliminated on disposal (1,419 )
At 28 February 2025 3,006
NET BOOK VALUE
At 28 February 2025 1,690
At 29 February 2024 1,767

5. FIXED ASSET INVESTMENTS
Other
investments
£   
COST OR VALUATION
At 1 March 2024 646,436
Additions 100,000
Revaluations 58,389
At 28 February 2025 804,825
NET BOOK VALUE
At 28 February 2025 804,825
At 29 February 2024 646,436

Cost or valuation at 28 February 2025 is represented by:

Other
investments
£   
Valuation in 2022 (4,645 )
Valuation in 2023 1,473
Valuation in 2024 49,608
Valuation in 2025 58,389
Cost 700,000
804,825

Lifescience Consultants Limited (Registered number: 05680172)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2025

5. FIXED ASSET INVESTMENTS - continued

If fixed asset investments had not been revalued they would have been included at the following historical cost:

2025 2024
£    £   
Cost 700,000 600,000

Fixed asset investments were valued on an open market basis on 28 February 2025 by Quilter .

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 23,412 25,481

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Taxation and social security 23,369 74,853
Other creditors 8,839 9,097
32,208 83,950

Included in other creditors is an amount owed to the director.

8. PROVISIONS FOR LIABILITIES
2025 2024
£    £   
Deferred tax
Accelerated capital allowances 423 442
Fair value reserve 36,365 11,035
36,788 11,477

Deferred
tax
£   
Balance at 1 March 2024 11,477
Movement in provision 25,311
Balance at 28 February 2025 36,788

Lifescience Consultants Limited (Registered number: 05680172)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2025

9. RESERVES
Fair
value
reserve
£   
At 1 March 2024 35,401
Non-distributable reserves 33,059

At 28 February 2025 68,460

The reserves in respect of investment revaluations are non distributable.